ArticleBMC health services research2026
Human papillomavirus (HPV) vaccination uptake (initiation and completion): factors associated with uptake of the human papillomavirus (HPV) vaccine among young people living with HIV in Uganda.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe prevalence of human papillomavirus (HPV) infection and related illnesses is disproportionately high in women and young people living with HIV. Vaccination against high-risk HPV types has the potential to reduce HPV- associated disease burden dramatically. However, HPV vaccine uptake has been variable and suboptimal in most countries, including Uganda, with low levels of both initiation and completion of the HPV doses. The purpose of this research was to identify determinants of HPV vaccine uptake and completion among young girls living with HIV.
methodsA cross-sectional study was conducted among 274 adolescents and young people living with HIV who were selected from an antiretroviral therapy (ART) clinic in a district Hospital ART clinic, Uganda. Data were collected between February and June 2024. The data were collected using a structured questionnaire examining HPV vaccine uptake (initiation and completion). Bivariate and multivariate analyses were conducted to assess factors associated with HPV vaccine uptake using SPSS version 21 software.
resultsThis study involved 274 participants, with a mean age of 20.3 years ranging from 15-24 years. The proportion who initiated HPV vaccination in this study was 68.2% (187/274), and HPV vaccine dose completion (2 doses and more) was 24.1% (66/274). The uptake of HPV vaccination was significantly associated with age 15 to 19 years (AOR 2.9, 95% CI 1.352-6.1 P = 0.006), having been taught about HPV vaccine and cervical cancer at school (AOR 8.7 95% CI 2.8-24.7, P = < 0.001), living within a distance of less than 5 km from the health facility (AOR 5.9, 95% CI 2.2-16.1, P = < 0.001), and availability of HPV vaccines at the health facility (AOR 5.2, 95% CI 1.9-14.5, P = < 0.001). The completion of HPV vaccination was significantly associated with age 20 to 24 years (AOR 1.9, 95% CI 1.057-3.499, P = 0.032).
conclusionThe initiation and completion of HPV vaccination among HIV- positive girls are both crucial for preventing HPV related diseases and cancers. In this study, the completion rate is very low. Vaccination against human papillomavirus (HPV) must be prioritised in the HIV-positive youth population. The findings suggest a need for targeted policies to improve vaccine uptake among HIV-positive youth, including better education, healthcare provider engagement, and system support for follow-up care. This will guide targeted interventions in achieving the WHO's target of 90% immunising all adolescent girls by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.